Updated on 11 September 2025
BD Outreach (Japan): Pipeline Building & Deal Origination for CDMOs and Biotechs
About
LinkedIn isn’t where deals close here (only 2% of Japanese uses while 20-50% in EU) —targeted outreach and native-language follow-through are.
-
Ideal-customer profiling and account mapping across big pharma, specialty pharma, and innovators.
-
Multilingual outreach (JP/EN), discovery calls, and qualification to real opportunities.
-
RFQ/RFI orchestration for CDMOs; asset/optioning conversations for biotechs.
-
Investor lane: introductions to strategic pharma/CVC, family offices, and non-dilutive programs; deck/localization coaching.
-
Meeting sprints around BioJapan/CPHI Japan plus rolling roadshows; weekly cadence reports in JST.
-
Term-sheet choreography with “cultural translation” to keep momentum and protect value.
Led by Moto Dohi (ex-Pfizer Japan; 10 years at a Swiss CDMO).
Type
- Consulting
Applies to
- Biotech and Lifescience
Similar opportunities
Service
Local Representation (Japan): Your On-the-Ground Team for CDMO & Biotech Growth
- Consulting
- Development
- Biotech and Lifescience